ScholarIQanswers from OpenAlex & ORCID
Shanu Modi
ResearcherPublications, citations & collaboration network
Shanu Modi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Shanu Modi have?
ScholarIQindexed works
Shanu Modi has 424 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Shanu Modi have?
ScholarIQcitation count
Shanu Modi has 20,054 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Shanu Modi?
ScholarIQh-index
Shanu Modi has an h-index of 61 in OpenAlex.
What is the i10-index of Shanu Modi?
ScholarIQi10-index
Shanu Modi has an i10-index of 157 in OpenAlex.
What is the ORCID of Shanu Modi?
ScholarIQorcid
The ORCID for Shanu Modi is on the source record.
What is the OpenAlex record for Shanu Modi?
ScholarIQopenalex
The OpenAlex for Shanu Modi is on the source record.
What are the most-cited papers on Shanu Modi?
ScholarIQmost cited works
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi, Matthew T. Chang, Guotai Xu, Chaitanya Bandlamudi, Dara S. Ross, Neil Vasan, Yanyan Cai, Craig M. Bielski, Mark T.A. Donoghue, Philip Jonsson, Alexander Penson, Ronglai Shen, Fresia Pareja, Ritika Kundra, Sumit Middha, Michael L. Cheng, Ahmet Zehir, Cyriac Kandoth, Ruchi Patel, Kety Huberman, Lillian M. Smyth, Komal Jhaveri, Shanu Modi, Tiffany A. Traina, Chau T. Dang, Wen Zhang, Britta Weigelt, Bob T. Li, Marc Ladanyi, David M. Hyman, Nikolaus Schultz, Mark E. Robson, Clifford A. Hudis, Edi Brogi, Agnès Viale, Larry Norton, Maura N. Dickler, Michael F. Berger, Christine A. Iacobuzio–Donahue, Sarat Chandarlapaty, Maurizio Scaltriti, Jorge S. Reis‐Filho, David B. Solit, Barry S. Taylor, José Baselga
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière, Stephen B. Solomon, Valerie W. Rusch, Roisin E. O’Cearbhaill, Amy Zhu, Waseem Cheema, Navin K. Chintala, Elizabeth Halton, John Pineda, Rocío Pérez-Johnston, Kay See Tan, Bobby Daly, Jose A. Araujo Filho, Daniel Ngai, Erin McGee, A. Vincent, Claudia Diamonte, Jennifer L. Sauter, Shanu Modi, Devanjan Sikder, Brigitte Sénéchal, Xiuyan Wang, William D. Travis, Mithat Gönen, Charles M. Rudin, Renier J. Brentjens, David R. Jones, Michel Sadelain